Introduction
Tumour stage is the most important prognostic factor for oesophageal cancer, a cancer characterised by a 5-year overall and postoperative survival of less than 15% and 35%, respectively. 1 Accurate cancer staging is crucial for predicting prognosis and deciding on treatment for these patients, and prognostic research heavily relies on accurate tumour stage data. The most commonly used staging system for oesophageal cancer is based on the TNM classification, which includes the local tumour growth (T), lymph node involvement (N) and distant metastases (M). TNM staging has been used since 1946 and has been updated regularly since, both by the Union
International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). 2, 3 TNM of oesophageal cancer is usually specified as clinical (cTNM) when it is based on findings from endoscopy and imaging prior to clinical decision-making, or pathological (pTNM) if it is based on a histological examination of a surgically resected specimen. Since pTNM is based on clinical information, supplemented or modified by the additional evidence acquired from surgery and from pathological examination, it is considered the most accurate way to report TNM. 4 Information from the Swedish Cancer Registry is often used in cancer research, including prognostic studies, which highlights the need for complete and correct TNM 
Material and Methods

Design
This was a validation study evaluating the completeness and accuracy of the including high-quality data on pTNM, which has previously been used to investigate causes, surgical treatment and outcome in oesophageal cancer. 5, 6 The study was approved by the Regional Ethical Review Board in Stockholm, Sweden.
Swedish Cancer Registry
The 
Comparison cohort
Our population-based surgery cohort study that was used as the comparison departments of pathology in Sweden were asked to send a copy of the histopathological record to the study secretariat for every patient in the study cohort. 5 Tumour stage, location, and histological type were manually reviewed by one investigator and two investigators checked a random sample of this classification and found it to be highly accurate. 5 Only patients with complete pTNM staging information were included in the comparison cohort. pTNM information was based on the histology reports and medical charts and defined by the 6 th edition of the TNM classification of the UICC. 4 Data were collected on the overall tumour stage as well as the separate T, N and M components.
Statistical analysis
Patients were classified into three TNM groups depending on whether the basis of the TNM was pathological (pTNM), clinical (cTNM), or unspecified (pTNM or cTNM). Patient-, tumour-, and treatment characteristics were compared, i.e. sex (male or female), age at diagnosis (three equally sized groups), tumour histology (adenocarcinoma or squamous cell carcinoma), calendar year of surgery (per year), hospital volume of oesophagectomies (three equally sized groups) and hospital type (university or non-university).
For each group, the TNM classification as reported in the Cancer Registry The categorisation of overall tumour stage used for our analyses is presented in Figure 1 . Accuracy was expressed as concordance or the proportion of all scores that were identical in both data sources. The Cohen's Kappa statistic was used to evaluate the concordance between variables from the two cohorts, with a Kappa of 1 indicating complete concordance. 10 All analyses were performed using the statistical software STATA (Stata Corp v13.0). 
Results
Patients
Basis of the tumour stage assessment in the Cancer Registry
Although the records of all study patients indicated that the cancer diagnosis in the Cancer Registry was based on "biopsy or operation with histopathological investigation", pTNM was reported for only 104 patients (26.2%), while cTNM was reported for 183 patients (46.1%). For the remaining 110 patients (27.7%) it was not specified if any TNM information was based on clinical or pathological examination ( Figure 2 ). As seen in Table 1 Table 1) .
Completeness of tumour stage and T, N, and M components in the Cancer Registry
For 395 out of 397 patients (99.5%) at least some information was reported on tumour stage or one or more of the T, N or M components in the Cancer
Registry. The overall completeness of tumour stage and the T, N, and M components in the Cancer Registry was 98.2%, 89.4%, 90.9%, and 85.1%, respectively. The completeness is presented in Table 2 for all three TNM groups (pTNM, cTNM, and unspecified basis for TNM). The completeness of tumour stage was similar in all three types of TNM assessments (range 98.1-98.4%)( Table 2 ). Most cases where T, N and M components were missing were patients in whom TNM was not specified. The completeness was higher for the pTNM data than the cTNM data for the T component (97.1% and 92.3%, respectively) and the N component (99.0% and 95.6%, respectively), while the M component was less complete in the pTNM group compared to the cTNM group (85.6% and 95.1%, respectively).
Accuracy of tumour stage and T, N, and M components in the Cancer
Registry
The overall reporting concordance and Kappa statistics are presented in Table 2 . Registry. 11 Another limitation is that we grouped some of the variables to obtain sufficiently large categories, including grouping of the tumour stage and T component into 4 groups rather than more specific categories. Finally, we did not have data on cTNM in the comparison cohort, which means that we could not validate this variable in any detail.
Although other validation studies have been performed to assess the quality of the Swedish Cancer Registry, 12, 13 this is to the best of our knowledge, the first validation study of the TNM staging in specific . It is unclear why pTNM is underreported, although it is requested from the Cancer Registry, and we cannot assess if differences in quality of TNM registration exist between the six regional cancer centres, or different hospitals. after neo-adjuvant therapy (which may have reduced the tumour size) or surgery (which allows histopathological examination and therefore more accurate staging). Unfortunately, the time point is not required to be reported when the information is submitted to the Cancer Registry. Although pTNM is the recommended TNM to report whenever available (which it is in all patients included in the present study), TNM was unclear or based on cTNM in the majority of patients, although it was stated that the diagnosis for all included patients was based on "biopsy or operation with histopathological investigation". Therefore, it may also be that the source of TNM is reported incorrectly as cTNM in some cases since the pathology data should have been available at that time. Unfortunately, distinguishing between biopsy and full histopathological investigation of the resected oesophagus was not possible because these data were not provided.
The main implications of these results are that pTNM is underreported, although it is requested by the Cancer Registry. However, the overall tumour stage is reliable for patients operated for oesophageal cancer, even when based on the cTNM or when it is unclear how the TNM is determined. In many cases, separate T, N and M components appeared to be unreliable.
The generalisability of these finding to other types of cancer are uncertain, but it is reasonable to assume that the problems encountered in the present study population would also exist for other tumours. However, the results might not be generalisable to non-operated patients, since the pTNM is not available.
To conclude, this nationwide Swedish validation study showed that the overall pTNM stage is incompletely reported, although this is compensated by a better reporting of cTNM staging and staging based on unspecified assessment. The T, N and M components are suboptimally reported. It is important to improve the assessment of tumour stage in the Swedish Cancer Registry, including making it clear by whom and when the reporting is supposed to be done, and highlighting the need to report both the cTNM and pTNM in operated cancer patients. Legend: pTNM, pathology based TNM staging; cTNM, clinically based TNM staging. *As reported in the Cancer Registry. Legend: pTNM, pathology based TNM staging; cTNM, clinically based TNM staging.
